Trodelvy: Transforming Breast Cancer Treatment with Innovative Therapies

Trodelvy (sacituzumab govitecan) is an innovative treatment for breast cancer that has shown significant promise in addressing various subtypes of the disease. It is the first antibody-drug conjugate approved by the FDA for the treatment of triple-negative breast cancer (TNBC) and metastatic TNBC. Trodelvy targets the protein Trop-2, which is present at high levels in TNBC and other cancers.

 How Trodelvy Works

Trodelvy, an antibody-drug conjugate, targets the protein Trop-2 highly expressed in TNBC. By binding to Trop-2, it facilitates the immune system’s recognition and attack on cancer cells. Additionally, Trodelvy delivers a cytotoxic payload, monomethyl auristatin E, causing damage to cancer cell DNA, leading to cell death. This dual mechanism disrupts cancer cell growth and promotes their elimination.

Clinical Evidence

Clinical trials have demonstrated the efficacy of Trodelvy in treating breast cancer. The ASCENT trial compared Trodelvy with single-agent chemotherapy in 529 patients with secondary TNBC. In the group without brain metastases, most patients on Trodelvy went on for 5.6 months without the cancer growing or spreading, compared to 1.7 months on chemotherapy. Additionally, Trodelvy has been approved to treat hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer as a third-line treatment option for patients who have received hormone (endocrine) therapy and two or more prior lines of treatment.

Safety and Future Implications

While Trodelvy can help put breast cancer into remission, it is important to note that it does not necessarily cure the disease. Trodelvy, like many targeted therapies, can also affect healthy cells. However, the development of Trodelvy represents a significant advancement in precision oncology, offering a more tailored and effective approach to treating various subtypes of breast cancer with fewer off-target side effects compared to previous treatments.

For those seeking to purchase Trodelvy 200 mg online, exclusively available in the US and Europe, Sansfro Health is a reliable option. Committed to streamlining the importation process, Sansfro Health provides accurate pricing information for a seamless experience. Sansfro facilitates the importation with authentic pricing and comprehensive assistance. 

Individuals interested in importing medication must provide a valid prescription, identity proof, healthcare professional details, and current address. The Sansfro team initiates the import license application, ensuring access to the necessary medication upon government approval. For inquiries about the price of Trodelvy in India and to understand the importation procedure, individuals can contact the Patient Support Team at (+91) 93157 05373 or via email at help@sansfro.com. 

Reference:

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf 
2. https://www.breastcancer.org/research-news/trodelvy-better-for-previously-treated-tnmbc 
3. https://owise.uk/trodelvy-secondary-breast-cancer/ 
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222657/ 
5. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer